Supplemental Table 5 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRASG12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRASG12D mutated patient-derived organoids.

补充表5A：MRTX1133处理后的KRASG12D患者来源类器官的药物敏感性指标。补充表5B：MRTX1133在不同剂量下对KRASG12D突变患者来源类器官的剂量反应关系。